Patent ID: 8921329
Filing Date: 2014-12-30
Classification: A61P,C07K,C12N,C12Q,Y10T

Abstract:
1. A method of upregulating a function of and/or the expression of an Erythropoietin (EPO) polynucleotide in patient cells or tissues in vivo or in vitro comprising: contacting said cells or tissues with at least one single stranded antisense oligonucleotide 10 to 30 nucleotides in length or a double stranded antisense oligonucleotide 19 to 30 nucleotides in length wherein said oligonucleotide has at least 80% sequence identity to a reverse complement of a polynucleotide comprising 10 to 30 or 19 to 30 nucleotides respectively within nucleotides 1 to 156 of a natural antisense oligonucleotide having SEQ ID NO: 3; thereby upregulating a function of and/or the expression of the Erythropoietin (EPO) polynucleotide in patient cells or tissues in vivo or in vitro.